Evaluated the Efficacy and Safety of APCP on Hair Health

N/ACompletedNCT06422026

Amorepacific Corporation150 enrolled

Overview

This study is designed to evaluate the efficacy and safety of APCP in promoting hair health in adult with mild to moderate hair damage, compared to a placebo control.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Enrollment

150

Conditions

Hair Damage

Interventions

APCP IDIETARY_SUPPLEMENT

Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.

APCP IIDIETARY_SUPPLEMENT

Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.

PlaceboDIETARY_SUPPLEMENT

Each subject takes one active bottle per day for 24 weeks.

Eligibility

Sex: ALLMin age: 19 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Glossy scores according to the visual evaluation classification method correspond to 1 point or more and 3 points or less and a total hair damage score of less than 18 points evaluated according to exposure to risk factors * A person capable of maintaining the same hair shape and color during this human body application test * A person who has agreed to participate in this human application test before the start of the human application test and filled out the Informed Consent Form Exclusion Criteria: * A person currently being treated for infectious diseases and malignant tumors, including severe cardiovascular system, immune system, respiratory system, hepatometer, kidney and urology system, nervous system, musculoskeletal system, psychosis, skin, etc * As of Visit 1, those who currently have dull dermatitis, scalp psoriasis, and scalp infection * A person who plans to manage and operate hair supplies, hair products during this human body application test * A person who has taken oral Dutasteride or Finasteride within 6 months of visit 1 * A person who has applied topical hair growth agents, wool, and hair growth agents for the last 1 month (30 days) or more as of Visit 1 * Those who have been administered systemic steroids, cell death agents, vasodilators, antihypertensive agents, antiepileptic agents, beta receptor blockers, bronchodilators, diuretics, Cimetidine, Diazoxide, Cyclosporine, and Ketoconazole for the last 1 month or more (30 days) * A person who has applied topical steroids to the scalp for the last 1 month (30 days) or more as of Visit 1 * A person who has participated in other interventional clinical trials (including human application tests) within one month (30 days) of visit 1 or plans to participate in other interventional clinical trials (including human application tests) after the start of this human application test * A person who is pregnant or who has a plan to become pregnant during the nursing mother or during this human body application test * A person who is sensitive to or allergic to food ingredients for this human body application test * A person who is deemed inappropriate by the tester for other reasons

Locations (1)

Yonsei University Health System, Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Change from baseline in hair tensile strength

Hair tensile strength measured by UTM(Universal Testing Machine) etc.

Time frame: Baseline, 24 week

Secondary Outcomes

Change from baseline in hair gloss

Hair gloss measured by Glossymeter etc.

Time frame: Baseline, 24 week

Change from baseline in hair density

Hair density measured by Folliscope

Time frame: Baseline, 24 week

Change from baseline in hair volume

Hair volume measured by I Max-plus

Time frame: Baseline, 24 week

Change from baseline in satisfaction survey

Satisfaction surveys are evaluated on a 10-point scale. Survey items are evaluated on a scale from '0 - Not at all' to '10 - Very much so' (although scoring may be reversed depending on the question).

Time frame: Baseline, 24 week

Change from baseline in scalp moisture

scalp moisture measured by DermaLab Hydration Pin Probe

Time frame: Baseline, 24 week

Change from baseline in scalp percutaneous moisture loss

scalp percutaneous moisture loss measured by Tewameter TM Nano

Time frame: Baseline, 24 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.